J S Millar

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339
    John S Millar
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Lipid Res 46:2023-8. 2005
  2. ncbi request reprint Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance
    Tongwei Yew
    Division of Endocrinology, Department of Medicine, National University Health System, Singapore, 1E Kent Ridge Road, Level 10, Singapore
    Recent Pat Cardiovasc Drug Discov 7:33-41. 2012
  3. pmc Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL
    John S Millar
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Lipid Res 52:136-42. 2011
  4. pmc Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels
    John S Millar
    The Institute for Translational Medicine and Therapeutics, The University of Pennsylvania, Philadelphia, USA
    Clin Transl Sci 3:140-6. 2010
  5. pmc Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice
    Junichiro Tohyama
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Atherosclerosis 204:418-23. 2009
  6. pmc Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
  7. ncbi request reprint Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
    John S Millar
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Lipid Res 49:543-9. 2008
  8. ncbi request reprint The sialylation of plasma lipoproteins
    J S Millar
    Department of Medicine, University of Pennsylvania, 621 BRB II III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    Atherosclerosis 154:1-13. 2001
  9. ncbi request reprint Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production
    John S Millar
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    J Lipid Res 47:2297-305. 2006
  10. ncbi request reprint Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans
    John S Millar
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:1350-6. 2006

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339
    John S Millar
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Lipid Res 46:2023-8. 2005
    ..Another nonionic detergent, poloxamer 407 (P-407), also inhibits LPL. In these studies, we demonstrate that P-407 is comparable to Triton in the determination of TG production but without the unwanted side effects of Triton...
  2. ncbi request reprint Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance
    Tongwei Yew
    Division of Endocrinology, Department of Medicine, National University Health System, Singapore, 1E Kent Ridge Road, Level 10, Singapore
    Recent Pat Cardiovasc Drug Discov 7:33-41. 2012
    ..Recent patents of novel approaches for the use of PPAR-γ related compounds with the potential for this improved risk-benefit ratio are discussed...
  3. pmc Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL
    John S Millar
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Lipid Res 52:136-42. 2011
    ..The change in HDL-C in response to rosiglitazone treatment was unrelated to effects on apoA-I, instead being related to the change in the metabolism of apoA-II...
  4. pmc Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels
    John S Millar
    The Institute for Translational Medicine and Therapeutics, The University of Pennsylvania, Philadelphia, USA
    Clin Transl Sci 3:140-6. 2010
    ....
  5. pmc Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice
    Junichiro Tohyama
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Atherosclerosis 204:418-23. 2009
    ..Studies were conducted to test the hypothesis that NNRTIs have a beneficial effect on HDL-C and reverse cholesterol transport (RCT)...
  6. pmc Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
    ..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...
  7. ncbi request reprint Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
    John S Millar
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Lipid Res 49:543-9. 2008
    ..Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL...
  8. ncbi request reprint The sialylation of plasma lipoproteins
    J S Millar
    Department of Medicine, University of Pennsylvania, 621 BRB II III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    Atherosclerosis 154:1-13. 2001
    ..Manipulations of the sialylation of apolipoproteins and of the quantity of apolipoproteins and gangliosides on lipoproteins will be useful methods in determining the role of lipoprotein sialic acid in the development of atherosclerosis...
  9. ncbi request reprint Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production
    John S Millar
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    J Lipid Res 47:2297-305. 2006
    ..In the presence of adequate cytoplasmic lipid stores, factors other than triglyceride synthesis are rate-limiting for VLDL production...
  10. ncbi request reprint Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans
    John S Millar
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:1350-6. 2006
    ..The goal of the present study was to define the kinetic mechanism(s) by which CETP inhibition reduces levels of apoB-containing lipoproteins...
  11. ncbi request reprint Normal production rate of apolipoprotein B in LDL receptor-deficient mice
    John S Millar
    Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
    Arterioscler Thromb Vasc Biol 22:989-94. 2002
    ..These results indicate that the LDL receptor has no effect on the production rate of VLDL triglyceride or apoB in vivo in mice...
  12. ncbi request reprint Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production
    John S Millar
    Department of Medicine, University of Pennsylvania, 644 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 25:560-5. 2005
    ..We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans...
  13. ncbi request reprint Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation
    Ryan E Moore
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Circ Res 97:763-71. 2005
    ....
  14. ncbi request reprint Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins
    Uli C Broedl
    University of Pennsylvania, Philadelphia, PA, USA
    Circ Res 94:1554-61. 2004
    ..In light of these results, inhibition of EL has the potential to raise levels of atherogenic lipoproteins in addition to HDL-C levels...
  15. doi request reprint Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice
    Ying Liu
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    Biochim Biophys Acta 1781:97-104. 2008
    ..Our findings indicate that the majority of TG destined for secretion by liver is synthesized by DGAT2 and suggests that DGAT2 may be a therapeutic target for treatment of hypertriglyceridemia, hepatic steatosis and obesity...
  16. pmc Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes
    Xiaoyu Li
    Institute for Translational Medicine and Therapeutics and Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Biochem Pharmacol 80:1450-7. 2010
    ..These results indicate that niacin-mediated activation of GP109A in liver lowers ABCA1 expression leading to reduced hepatic cholesterol efflux to HDL...
  17. ncbi request reprint Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II
    Uli C Broedl
    Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Lipid Res 47:2191-7. 2006
    ..We conclude that the presence of apoA-II on HDL particles inhibits the ability of EL to influence the metabolism of HDL in vivo...
  18. doi request reprint The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans
    Ashish Shah
    University of Pennsylvania, Depts of Medicine and Pharmacology, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, United States
    Atherosclerosis 210:35-40. 2010
    ..However, the benefit of the enhanced turnover of HDL apoA-I in response to PPAR-alpha activation remains to be determined...
  19. pmc Novel ENU-induced point mutation in scavenger receptor class B, member 1, results in liver specific loss of SCARB1 protein
    Ioannis M Stylianou
    School of Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 4:e6521. 2009
    ..This new Scarb1 model may help further our understanding of post-translational and tissue-specific regulation of SCARB1 that may aid the important clinical goal of raising functional HDL...
  20. pmc Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo
    William R Lagor
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:40-6. 2009
    ..It is also known as lipid transfer inhibitor protein (LTIP) based on its ability to inhibit lipid transfer between lipoproteins ex vivo. We sought to investigate the role of ApoF in HDL metabolism...
  21. ncbi request reprint Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway
    Ilia V Fuki
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 278:34331-8. 2003
    ..002 via LpL. In summary, EL mediates binding and uptake of plasma lipoproteins via a process that is independent of its enzymatic activity, requires cellular heparan sulfate proteoglycans, and is regulated by ligand clustering...
  22. pmc Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol
    François Briand
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Transl Sci 2:127-33. 2009
    ..In conclusion, PPARdelta activation enhances excretion of macrophage or HDL-derived cholesterol in feces through reduced NPC1L1 expression in mice, comparable to the effect of ezetimibe...
  23. pmc Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo
    Weijun Jin
    Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 111:357-62. 2003
    ..We conclude that inhibition of EL results in increased HDL-C levels and that EL is an important enzyme in the physiological regulation of HDL metabolism...
  24. pmc Hepatic proprotein convertases modulate HDL metabolism
    Weijun Jin
    Department of Pharmacology, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cell Metab 6:129-36. 2007
    ..The hepatic PC-ANGPTL3-EL-HDL pathway is therefore a novel mechanism controlling HDL metabolism and cholesterol homeostasis...
  25. pmc Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages
    Marina Cuchel
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Maloney Building, Room 8039, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 30:526-32. 2010
    ..We performed studies to identify the underlying molecular mechanisms by which rHDL promote FC mobilization from whole body in vivo and macrophages in vitro...
  26. ncbi request reprint Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor
    Ryan E Moore
    University of Pennsylvania School of Medicine, 654 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 23:1914-20. 2003
    ..We examined the effects of apoA-I deficiency on plasma lipids and atherosclerosis in LDL receptor-deficient mice fed a chow diet for up to 22 months...
  27. ncbi request reprint Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
    Marina Cuchel
    University of Pennsylvania School of Medicine, Philadelphia, USA
    N Engl J Med 356:148-56. 2007
    ..Inhibition of the microsomal triglyceride transfer protein may be effective in reducing cholesterol levels in these patients...
  28. ncbi request reprint The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings
    Jennifer L Jenner
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA
    Metabolism 54:361-9. 2005
    ....
  29. pmc Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA HNRCA at Tufts University and Tufts New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 25:1057-64. 2005
    ..The present study was designed to address these issues...
  30. ncbi request reprint Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]
    William J Cain
    Department of Biological Sciences, University of Delaware, Newark, DE, USA
    J Lipid Res 46:2681-91. 2005
    ..Our studies indicate that apo[a] is the primary ligand that mediates Lp[a] uptake and plasma clearance...